Abstract
Objective: To review the consequences of nonadherence to antipsychotic pharmacotherapy in patients with schizophrenia, as well as associated risk factors for nonadherence and methods of improving adherence. Methods: Review of the literature based on a MEDLINE search on the terms schizophrenia and adherence or compliance, limited to the English language, supplemented by the authors own knowledge of the topic. Results: Nonadherence to antipsychotic therapy is a common reason for relapse and rehospitalization of patients with schizophrenia and thus contributes to the high cost of treating psychoses, adverse events, and lack of insight. Comorbid substance abuse, little family involvement, and a poor clinician-patient relationship are among the risk factors for nonadherence. Patients with a negative attitude towards treatment, which can result from adverse events, are also more likely to be nonadherent. Strategies to improve adherence include optimizing antipsychotic therapy, minimizing adverse events, encouraging patient participation in psychoeducational programs, treating comorbid substance abuse disorders, involving family members in the treatment process, and forging a close therapeutic relationship with the patient. Conclusions: Improving adherence is difficult but necessary for achieving optimal treatment outcomes. Careful selection of drug therapy, with emphasis on a drugs tolerability, combined with nonpharmacologic interventions, may help decrease nonadherence in patients with schizophrenia.
Keywords: Adherence, Antipsychotic, Nonadherence, Schizophrenia
Current Clinical Pharmacology
Title: Improving Adherence to Antipsychotic Pharmacotherapy
Volume: 1 Issue: 1
Author(s): Prakash S. Masand and Meera Narasimhan
Affiliation:
Keywords: Adherence, Antipsychotic, Nonadherence, Schizophrenia
Abstract: Objective: To review the consequences of nonadherence to antipsychotic pharmacotherapy in patients with schizophrenia, as well as associated risk factors for nonadherence and methods of improving adherence. Methods: Review of the literature based on a MEDLINE search on the terms schizophrenia and adherence or compliance, limited to the English language, supplemented by the authors own knowledge of the topic. Results: Nonadherence to antipsychotic therapy is a common reason for relapse and rehospitalization of patients with schizophrenia and thus contributes to the high cost of treating psychoses, adverse events, and lack of insight. Comorbid substance abuse, little family involvement, and a poor clinician-patient relationship are among the risk factors for nonadherence. Patients with a negative attitude towards treatment, which can result from adverse events, are also more likely to be nonadherent. Strategies to improve adherence include optimizing antipsychotic therapy, minimizing adverse events, encouraging patient participation in psychoeducational programs, treating comorbid substance abuse disorders, involving family members in the treatment process, and forging a close therapeutic relationship with the patient. Conclusions: Improving adherence is difficult but necessary for achieving optimal treatment outcomes. Careful selection of drug therapy, with emphasis on a drugs tolerability, combined with nonpharmacologic interventions, may help decrease nonadherence in patients with schizophrenia.
Export Options
About this article
Cite this article as:
Masand S. Prakash and Narasimhan Meera, Improving Adherence to Antipsychotic Pharmacotherapy, Current Clinical Pharmacology 2006; 1 (1) . https://dx.doi.org/10.2174/157488406775268255
DOI https://dx.doi.org/10.2174/157488406775268255 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Adherence to Treatment, Arterial Stiffness and Cognitive Function in Irbesartan- Treated Newly Diagnosed Hypertensive Patients
Current Vascular Pharmacology Subject Index To Volume 3
Vascular Disease Prevention (Discontinued) Selenium-Enriched Yeast: As Selenium Source for Nutritional Purpose
Current Nutrition & Food Science Oligonucleotide Aptamers for Glioma Targeting: An Update
Central Nervous System Agents in Medicinal Chemistry Antiplatelet Treatment in Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Pathogenetic Pathways of Cardiorenal Syndrome and their Possible Therapeutic Implications
Current Pharmaceutical Design Traditional Chinese Medicine Network Pharmacology in Cardiovascular Precision Medicine
Current Pharmaceutical Design Applied Proteomics in Companion Animal Medicine
Current Proteomics Genes, Environment, Intermediate Phenotypes, and the Pathogenesis of Diabetic Nephropathy
Current Pharmacogenomics Atherosclerosis is an Inflammatory Disorder After All
Current Topics in Medicinal Chemistry Psychological Sequelae of Ovarian Cancer Screening and Genetic Testing for Ovarian Cancer Susceptibility
Current Women`s Health Reviews Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics Physiologic Tailoring of Treatment in Resistant Hypertension
Current Cardiology Reviews Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD)
Current Gene Therapy NPY Y1 and Y5 Receptor Selective Antagonists as Anti-Obesity Drugs
Current Topics in Medicinal Chemistry Perceval Sutureless Valve – are Sutureless Valves Here?
Current Cardiology Reviews Profile of IKs During the Action Potential Questions the Therapeutic Value of IKs Blockade
Current Medicinal Chemistry Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds Cellular Repressor of E1A-stimulated Genes, A New Potential Therapeutic Target for Atherosclerosis
Current Drug Targets Preventive Effect of Soybean on Brain Aging and Amyloid-β Accumulation: Comprehensive Analysis of Brain Gene Expression
Recent Patents on Food, Nutrition & Agriculture